InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

September 24, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – September 24, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its second Phase 1 clinical trial with INM-755 … Continue reading InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

September 23, 2020
Janssen Pharmaceutical Companies

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, … Continue reading Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

CANADIAN HEALTHCARE GAINS ACCESS TO NATIONAL STUDENT PLACEMENT PROGRAM

BioTalent Canada

OTTAWA, September 22, 2020 – BioTalent Canada is expanding its successful national Student Work Placement Program (SWPP) to Canadian healthcare for the first time. Providing wage subsidies to healthcare students builds on BioTalent Canada’s successful track record of delivering SWPP in the bioscience industry since 2017. Over the past three years, with its many wage subsidy programs including … Continue reading CANADIAN HEALTHCARE GAINS ACCESS TO NATIONAL STUDENT PLACEMENT PROGRAM

InMed Pharmaceuticals Announces Additional IntegraSynTM Patent Filing

September 22, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – September 22, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced the filing of a patent application as part of a growing portfolio of … Continue reading InMed Pharmaceuticals Announces Additional IntegraSynTM Patent Filing

Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates

September 21, 2020
Kintara Therapeutics, Inc.

SAN DIEGO, Sept. 21, 2020 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the year ended June 30, 2020 and provided a corporate update. “The past fiscal year was one of the most important periods in … Continue reading Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates

Unleashing Canada’s Radiopharmaceutical Excellence

September 17, 2020
adMare BioInnovations

New Pan-Canadian Partnership Looks to Commercialize the Country’s Most Promising Radiopharmaceutical Innovations September 17, 2020: The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic … Continue reading Unleashing Canada’s Radiopharmaceutical Excellence

Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

September 16, 2020
AbCellera Biologics Inc.

Interim data suggests that LY-CoV555 has a direct antiviral effect and may reduce COVID-related hospitalizations VANCOUVER, British Columbia, September 16, 2020 – AbCellera today announced that interim data from a Phase 2 clinical trial of LY-CoV555, the first antibody to emerge from AbCellera’s collaboration with Eli Lilly and Company (Lilly) to create antibody therapies for … Continue reading Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

Symvivo Announces Appointment of Lloyd Mackenzie as President and Chief Operating Officer

Symvivo Corp.

BURNABY, British Columbia, September 16th, 2020 – Symvivo Corporation today announced the appointment of Lloyd Mackenzie as the company’s President and Chief Operating Officer.  Mr. Mackenzie is a biotechnology Research and Development executive with over 25 years of experience in drug development, manufacturing and control, quality assurance, clinical development and clinical operations.  Mr. Mackenzie was … Continue reading Symvivo Announces Appointment of Lloyd Mackenzie as President and Chief Operating Officer